

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



**Transcenta Holding Limited**  
**創勝集團醫藥有限公司**

*(registered by way of continuation in the Cayman Islands with limited liability)*

**(Stock code: 6628)**

**NOTICE OF EXTRAORDINARY GENERAL MEETING**

**NOTICE IS HEREBY GIVEN THAT** the extraordinary general meeting (“**EGM**”) of Transcenta Holding Limited (the “**Company**”) will be held 218 Xinghu Street, Biobay, B6-501, Suzhou, China on March 9, 2023 at 10:00 a.m. for the purpose of considering and, if thought fit, passing the following resolutions as ordinary resolution of the Company:

**ORDINARY RESOLUTIONS**

1. “**THAT** the grant 4,400,000 restricted share units (“**RSUs**”) to Mr. Weng, who is an executive director (“**Director**”), chief financial officer of the Company, entitling him to 4,400,000 ordinary shares of US\$0.001 each (the “**Shares**”) in the share capital of the Company (the principal terms and conditions of such grant are set out in the circular of the Company dated February 16, 2023 (the “**Circular**”) under and pursuant to the Pre-IPO Equity Incentive Plan of the Company adopted on January 1, 2019 (the “**Pre-IPO Equity Incentive Plan**”) and on such terms as stipulated in the award letter issued by the Company pursuant to the Pre-IPO Equity Incentive Plan be and is hereby approved, confirmed and ratified, **THAT** the board of Directors of the Company (“**Board**”) be and is hereby authorized to exercise all rights and powers available to it as it may in its sole discretion consider necessary or expedient to give full effect to the grant of the 4,400,000 RSUs to Mr. Weng, and **THAT** any and all such acts to effect the aforesaid grant be and are hereby approved, confirmed and ratified.”
2. “**THAT** the grant of 3,641,024 Options to Dr. Qian, who is an executive Director and the Chief Executive Officer of the Company, and the grant of 4,853,181 Options to Dr. Zhao, who is a non-executive Director of the Company, entitling Dr. Qian to subscribe for 3,641,024 Shares at an exercise price of HK\$3.02 per Share and entitling Dr. Zhao to subscribe for 4,853,181 Shares at an exercise price of HK\$3.02 per Share (the principal terms and conditions of such grant are set out in the Circular) pursuant to the share incentive scheme of the Company approved by the Shareholders of the Company on November 4, 2022 (the “**Share Incentive Scheme**”) and on such terms as stipulated in the option letter issued by the Company pursuant to the Share Incentive Scheme be and is hereby approved, confirmed and ratified, **THAT** the Board be and is hereby authorized to exercise all rights and powers available to it as it may in its sole discretion consider necessary or expedient to give full effect to the grant of the 3,641,024 Options to Dr. Qian, the grant of the

4,853,181 Options to Dr. Zhao and the issue of the Shares upon the exercise of the Options by Dr. Qian and Dr. Zhao, respectively, and **THAT** any and all such acts to effect the aforesaid grant be and are hereby approved, confirmed and ratified.”

3. “**THAT** the grant of 4,277,188 Award Shares to Dr. Qian and the grant of 198,997 Award Shares to Dr. Zhao (the principal terms and conditions of such grant are set out in the Circular) pursuant to the Share Incentive Scheme and on such terms as stipulated in the award letter issued by the Company pursuant to the Share Incentive Scheme be and is hereby approved, confirmed and ratified, **THAT** the Board be and is hereby authorized to exercise all rights and powers available to it as it may in its sole discretion consider necessary or expedient to give full effect to the grant of the 4,277,188 Award Shares to Dr. Qian, the grant of the 198,997 Award Shares to Dr. Zhao and the issue of the Shares upon the vesting of the Award Shares of Dr. Qian and Dr. Zhao, respectively, and **THAT** any and all such acts to effect the aforesaid grant be and are hereby approved, confirmed and ratified.”

Yours faithfully  
By Order of the Board  
**Transcenta Holding Limited**  
**Dr. Yining (Jonathan) Zhao**  
*Chairman*

Hong Kong, February 16, 2023

*Registered Office:*  
Walkers Corporate Limited  
190 Elgin Avenue, George Town  
Grand Cayman KY1-9008  
Cayman Islands

*Principal Place of Business in Hong Kong:*  
5/F, Manulife Place  
348 Kwun Tong Road  
Kowloon  
Hong Kong

*Notes:*

1. A form of proxy for use at the EGM is enclosed.
2. A Shareholder entitled to attend and vote at the above meeting is entitled to appoint another person as his/her/its proxy to attend and vote instead of him/her/it; a proxy need not be a shareholder of the Company.
3. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the vote(s) of the other joint holder(s), and for this purpose, seniority shall be determined as that one of the said persons so present whose name stands first on the register in respect of such Share shall alone be entitled to vote in respect thereof.
4. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours before the time appointed for the meeting (i.e. not later than 10:00 a.m on Tuesday, March 7, 2023 (Hong Kong time)) or the adjourned meeting (as the case may be). Completion and return of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
5. For determining the entitlement to attend and vote at the meeting, the Register of Members of the Company will be closed from Monday, March 6, 2023 to Thursday, March 9, 2023, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Extraordinary General Meeting, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Friday, March 3, 2023.
6. In accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the above resolutions will be voted by poll; Mr. Weng (as defined in the Circular) and all core connected persons (as defined in the Circular) of the Company are required to abstain from voting in respect of resolutions numbered 1 above; and Dr.Qian and Dr. Zhao (as defined in the Circular) and all core connected persons (as defined in the Circular) of the Company are required to abstain from voting in respect of resolutions numbered 2 and 3 above.
7. References to time and dates in this notice are to Hong Kong time and dates.

*As at the date of this notice, the board of directors of the Company comprises Dr. Xueming Qian as executive Director and chief executive officer, Mr. Xiaolu Weng as executive Director, Dr. Yining (Jonathan) Zhao as chairman and non-executive Director, and Mr. Jiasong Tang, Dr. Jun Bao, Mr. Zihua Zhang and Dr. Kumar Srinivasan as independent non-executive Directors.*